The Global Cervical Cancer Diagnostic Market valued for $7.8 billion in 2022 and is estimated to reach $12.6 billion by 2032, exhibiting a CAGR of 5% from 2023 to 2032.
Cervical cancer is a type of cancer found anywhere in the cervix. The cervix is the opening between the vagina and the womb (uterus). It is part of the reproductive system and is sometimes called the neck of the womb. Nearly all cervical cancers are caused by an infection from certain types of human papillomavirus (HPV). Although cervical cancers start from cells with pre-cancerous changes (pre-cancers), only some of the women with pre-cancers of the cervix will develop cancer. For most women, pre-cancerous cells will go away without any treatment. But, in some women pre-cancers turn into true (invasive) cancers. Treating cervical pre-cancers can prevent almost all cervical cancers. The goal of cervical cancer screening is to find pre-cancer or cancer early when it is more treatable and curable. Regular screening can prevent cervical cancers and save lives. The tests for cervical cancer screening are HPV test and the Pap test.
The growth of the cervical cancer diagnostic market is driven by increase in number of research and development activities, rise in prevalence of cervical cancer, surge in expenditure on the product development by the government and private organizations and increase in the technological advancements of the diagnostics tests products and increase the number of hospital visits of the patients for cancer screening. For instance, according to the data by the Centers of Disease Control and Prevention (CDC), published in August 2022, about 13,000 new cases of cervical cancer are diagnosed and about 4,000 women died due to this cancer each year in the U.S. Similarly, 12,795 new cases of cervical cancer were reported among women, and 4,152 women died of this cancer. For every 100,000 women, 8 new cervical cancer cases were reported, and 2 women died of this cancer in 2019, the year for which incidence data was available in the U.S.
Moreover, increase in research pipeline among the diagnostic research organizations and rise in awareness about strictness in the cancer screening also helps in the growth of the market. For instance, according to the data of the World Health Organization (WHO), January is celebrated as Cervical Cancer Awareness Month. It gives a perfect opportunity for World Health Organization and partners to raise awareness about cervical cancer and HPV vaccination. It also focuses on the elimination of cervical cancer as the theme for its Cervical Cancer Awareness Month. However, HPV vaccination, inaccurate pap smear testing and the availability of other types of screening of cervical cancer are expected to hinder the growth of the market.
The cervical cancer diagnostic market is segmented on the basis of type, age group and region. On the basis of type, the market is categorized into pap smear tests, HPV test, biopsy and ECC, colposcopy tests and others. On the basis of age group, the market is classified into 20 to 40 years, and above 40 years. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major companies profiled in the report include Abbott Laboratories, Qaigen NV, Carl Zeiss AG, Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Hologic Inc, F. Hoffmann-La Roche AG, Siemens Healthineers, CooperSurgical Inc., and Dysis Medical ltd.
Cervical cancer is a type of cancer found anywhere in the cervix. The cervix is the opening between the vagina and the womb (uterus). It is part of the reproductive system and is sometimes called the neck of the womb. Nearly all cervical cancers are caused by an infection from certain types of human papillomavirus (HPV). Although cervical cancers start from cells with pre-cancerous changes (pre-cancers), only some of the women with pre-cancers of the cervix will develop cancer. For most women, pre-cancerous cells will go away without any treatment. But, in some women pre-cancers turn into true (invasive) cancers. Treating cervical pre-cancers can prevent almost all cervical cancers. The goal of cervical cancer screening is to find pre-cancer or cancer early when it is more treatable and curable. Regular screening can prevent cervical cancers and save lives. The tests for cervical cancer screening are HPV test and the Pap test.
The growth of the cervical cancer diagnostic market is driven by increase in number of research and development activities, rise in prevalence of cervical cancer, surge in expenditure on the product development by the government and private organizations and increase in the technological advancements of the diagnostics tests products and increase the number of hospital visits of the patients for cancer screening. For instance, according to the data by the Centers of Disease Control and Prevention (CDC), published in August 2022, about 13,000 new cases of cervical cancer are diagnosed and about 4,000 women died due to this cancer each year in the U.S. Similarly, 12,795 new cases of cervical cancer were reported among women, and 4,152 women died of this cancer. For every 100,000 women, 8 new cervical cancer cases were reported, and 2 women died of this cancer in 2019, the year for which incidence data was available in the U.S.
Moreover, increase in research pipeline among the diagnostic research organizations and rise in awareness about strictness in the cancer screening also helps in the growth of the market. For instance, according to the data of the World Health Organization (WHO), January is celebrated as Cervical Cancer Awareness Month. It gives a perfect opportunity for World Health Organization and partners to raise awareness about cervical cancer and HPV vaccination. It also focuses on the elimination of cervical cancer as the theme for its Cervical Cancer Awareness Month. However, HPV vaccination, inaccurate pap smear testing and the availability of other types of screening of cervical cancer are expected to hinder the growth of the market.
The cervical cancer diagnostic market is segmented on the basis of type, age group and region. On the basis of type, the market is categorized into pap smear tests, HPV test, biopsy and ECC, colposcopy tests and others. On the basis of age group, the market is classified into 20 to 40 years, and above 40 years. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major companies profiled in the report include Abbott Laboratories, Qaigen NV, Carl Zeiss AG, Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Hologic Inc, F. Hoffmann-La Roche AG, Siemens Healthineers, CooperSurgical Inc., and Dysis Medical ltd.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global cervical cancer diagnostic market analysis from 2022 to 2032 to identify the prevailing global cervical cancer diagnostic market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the global cervical cancer diagnostic market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as GLOBAL cervical cancer diagnostic market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
- Pap Smear Tests
- HPV test
- Biopsy and ECC
- Colposcopy Tests
- Others
By Age group
- 20 to 40 years
- above 40 years
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Abbott Laboratories
- Becton, Dickinson and Company
- Carl Zeiss AG
- CooperSurgical Inc.
- Dysis Medical ltd.
- F. Hoffmann-La Roche AG
- Hologic Inc.
- Qaigen NV
- Siemens Healthineers
- Thermo Fisher Scientific Inc.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: CERVICAL CANCER DIAGNOSTIC MARKET, BY TYPE
CHAPTER 5: CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP
CHAPTER 6: CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION
CHAPTER 7: COMPETITIVE LANDSCAPE
CHAPTER 8: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Abbott Laboratories
- Becton, Dickinson and Company
- Carl Zeiss AG
- CooperSurgical Inc.
- Dysis Medical ltd.
- F. Hoffmann-La Roche AG
- Hologic Inc.
- Qaigen NV
- Siemens Healthineers
- Thermo Fisher Scientific Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
